Company
United StatesPublic company, NASDAQ: SRPTSarepta Therapeutics Inc (NASDAQ: SRPT), Andover, MA – FDA Inspections
Inspection records and compliance data for Sarepta Therapeutics Inc in Andover, Massachusetts. 2 FDA inspections on record, 1 Form 483, last inspected July 15, 2025. Publicly traded as NASDAQ: SRPT.
Company Profile
This profile covers Sarepta Therapeutics Inc based in Andover, Massachusetts, United States.
FDA Inspection History
- FDA inspections
- 2
- OAI
- 0
- VAI
- 1
- NAI
- 1
- Form 483s
- 1
- Warning letters
- 0
First inspected March 24, 2023. Last inspected July 15, 2025.
Most cited issue areas
- Authority lacking to review records, investigate errors1 inspection
FDA inspections (2)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| July 15, 2025 | NAI | Biologics · Human Cellular, Tissue, and Gene Therapies | 1277727 |
| March 24, 2023 | VAI | Biologics | 1200687 |
FDA documents
Form 483s (1)
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Emergent Biosolutions LLC
GlaxoSmithKline Vaccines S.r.l.
Juno Therapeutics Inc, a subsidiary of Bristol-Myers Squibb
North American Science Associates, LLC
Haematologic Technologies, LLC dba Prolytix
Nelson Laboratories, LLC
Eurofins Lancaster Laboratories, Inc
Takeda Manufacturing Austria AG
Associates of Cape Cod, Inc.
Bioreliance Corporation
Company Information
Name
Sarepta Therapeutics Inc
Stock ticker
SRPT
Exchange
NASDAQ
Share price
$16.01
Market cap
$1.7B
Price as of
November 13, 2026
FEI Number
3012807588
Address
100 Federal St, Andover, Massachusetts 01810, United States
Country
United States
ID: 5a8d2168-ec04-4530-a81f-00bab06c4a44